Document:

EX-10.2

 Exhibit 10.2 

EXECUTIVE EMPLOYMENT AGREEMENT 

This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) between Eloxx Pharmaceuticals, Inc. (the “Company”),
and Gregory C. Williams (the “Executive”) is dated as of June 22 2018 and shall become effective on June 25, 2018 (the “Effective Date”). 

W I T N E S S E T H: 
 WHEREAS,
the Company desires the Executive to provide employment services to the Company, and wishes to provide the Executive with certain compensation and benefits in return for such employment services; and 

WHEREAS, the Executive wishes to be employed by the Company and to provide employment services to the Company in return for certain
compensation and benefits; 
 NOW THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.
EMPLOYMENT TERM. The Company hereby offers to employ the Executive, and the Executive hereby accepts employment by the Company, upon the terms and conditions set forth in this Agreement, during the period commencing on the Effective
Date and ending on the date of the termination of the Executive’s employment in accordance with Section 7 below (the “Employment Term”). The Executive shall be employed at will, meaning that either the Company or the
Executive may terminate this Agreement and the Executive’s employment at any time, for any reason or no reason, with or without cause, subject to the terms of this Agreement. 

2. POSITION & DUTIES. 

(a) Except as provided in Section 2(b) below, the Executive shall serve as the Chief Operating Officer of the Company and its US
subsidiary, Eloxx Pharmaceuticals U.S. Sub, Inc. during the Employment Term. As Chief Operating Officer, the Executive shall have such duties, authorities and responsibilities as are commensurate with the position of Chief Operating Officer and such
other duties and responsibilities as the Company’s Chief Executive Officer shall designate that are consistent with the Executive’s position as Chief Operating Officer. 

(b) During the Employment Term, the Executive agrees to devote his full business time, attention and energies to the performance of all of the
lawful duties, responsibilities and authority that may be assigned to him hereunder. Nothing contained in this Agreement will preclude the Executive from (i) devoting time to personal and family investments, (ii) serving as a director of
any not-for-profit company, (iii) serving as a director for any for-profit company that is approved by the Chief Executive
Officer (such approval not to be unreasonably withheld) or (iv) from participating in charitable or industry associations, in each case, provided that such activities or services do not (x) materially interfere with the
Executive’s performance of duties hereunder or (y) violate the terms of the Confidentiality Agreement (as defined below). 

  
 1 of 13 

 (c) During the Employment Term, the Executive’s principal place of employment shall
be his home office in New Jersey, subject to customary business travel consistent with the Executive’s duties and responsibilities. 

3. BASE SALARY. The Company agrees to pay the Executive a base salary (the “Base Salary”) at an annual rate of
US$ 375,000. The Base Salary will be payable bimonthly in accordance with the regular payroll practices of the Company. The Executive’s Base Salary shall be subject to review by the Board (or a Committee thereof) at least annually and may be
increased, but not decreased, from time to time by the Board. The base salary as determined herein from time to time shall constitute “Base Salary” for purposes of this Agreement. 

4. BONUSES. 
 (a)
ANNUAL BONUS. With respect to each full calendar year during the Employment Term, the Executive shall be eligible to earn an annual, performance-based bonus (an “Annual Bonus”) with a target bonus value equal to forty percent
(40%) of the Executive’s Base Salary (the “Target Bonus”) based upon the achievement of performance targets, which shall be established by the Board (or a committee thereof) in consultation with the Executive within the first
90 days of each calendar year during the Employment Term, with the actual amount of the Annual Bonus for a particular year determined by the Board (or a committee thereof) in its discretion. The Board (or a committee thereof) shall consider the
Executive’s performance in the entire 2018 calendar year without regard to the effective date when determining the Executive’s Annual Bonus for the 2018 calendar year (i.e. the Executive, at the Board’s discretion, will be eligible
for a 12-month bonus for 2018 and not be limited to a prorated bonus for the portion of 2018 that the Executive is employed by the Company). Subject to Section 8 below, in order to be eligible for an
Annual Bonus, the Executive must remain employed for the entire calendar year for which the performance targets will have been set. Any Annual Bonus earned by the Executive will be paid no later than March 15 of the calendar year immediately
following the calendar year in which the Annual Bonus is being measured. The Executive’s Target Bonus shall be subject to review by the Board (or a committee thereof) at least annually and may be increased, but not decreased, from time to time
by the Board. 
 (b) SIGNING BONUS. In addition, the Company shall pay to the Executive a signing bonus of $50,000 on the first
regularly scheduled payroll following the Executive’s first day of employment. 
 5. EQUITY COMPENSATION. The Company
will grant to the Executive on the first day of employment following the Effective Date (the “Grant Date”) equity compensation awards under the 2018 Equity Incentive Plan (as amended, the “Plan”) for share of the Company’s
common stock (“Common Stock”) as follows: 
 (a) TIME-VESTING AWARDS. A stock option to purchase
300,000 shares of Common Stock on the Grant Date that will vest and become exercisable or payable, respectively, with respect to 1/3 of the shares on the first anniversary of the Effective Date of this Agreement and with respect to an additional
1/12 of the shares on each quarterly anniversary of the Grant Date thereafter, subject to the Executive’s continued employment with the Company through each such date. In addition, the vesting of the time vesting

  
 2 of 13 

 
awards above, and any future stock options, restricted stock units or other equity compensation awards granted to the Executive, shall be accelerated and become fully vested and exercisable or
payable, respectively, immediately prior to a Significant Event (as defined in the 2013 Share Ownership and Option Plan) 
 (c) ANNUAL
AWARDS. Each year, the Executive will be eligible for annual awards of stock options and or restricted stock units as determined by the Board. Nothing herein shall be construed as an obligation to grant such awards, which shall be subject to the
sole discretion of the Board. 
 (d) TAX WITHHOLDING. At Executive’s request, the Company will withhold from the shares of
Common Stock otherwise payable to Executive with respect to vested portions of the Time-Vesting Shares the number of whole shares of Common Stock required to satisfy the applicable tax withholding obligation, the number of shares so withheld to be
determined by the Company based on the fair market value of the Common Stock on the date the Company is required to withhold. 
 6.
EMPLOYEE BENEFITS. 
 (a) BENEFIT PLANS. The Executive shall be entitled to participate in all employee benefit plans
that the Company generally makes available to its senior executives (other than severance plans) from time to time, including any group health plans, dental plans, life, disability and AD&D insurances, a 401(k) plan, tuition reimbursement,
recreation allowance, parking or public transportation and various types of paid time off, subject to the terms and conditions of such benefit plans. The Executive may elect to continue with COBRA insurance from the Executive’s prior employer,
and in such an event, the Company will reimburse the Executive for 100% of the Executive’s out of pocket cost of COBRA insurance coverage from Executive’s prior employer. 

(b) VACATION. The Executive shall be entitled to twenty (20) days of paid vacation per year, in accordance with the Company’s
vacation policy; provided that the Executive shall be entitled to twenty-five (25) days of paid vacation per year after three (3) full calendar years of employment. Vacation may be taken at such times as the Executive elects
with due regard to the needs of the Company. 
 (c) BUSINESS EXPENSES. The Company will reimburse the Executive for all reasonable
business expenses incurred by the Executive in connection with the discharge of his duties for the Company, subject to the Company’s expense reimbursement policy in effect from time to time. 

(d) INDEMNIFICATION. The Company shall indemnify the Executive to the maximum extent that its officers, directors and employees are
entitled to indemnification pursuant to the Company’s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being a director, officer or employee of the Company as of the Effective Date. At all times during the
Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer and director. 

  
 3 of 13 

 7. TERMINATION. The Executive’s employment and the Employment Term shall
terminate on the first of the following to occur: 
 (a) DISABILITY. Upon the
30th day following the Executive’s receipt of notice of the Company’s intention to terminate the Executive’s employment due to Disability (as defined in this Section 7(a));
provided that, the Executive has not returned to full-time performance of his duties within 30 days after receipt of such notice. If the Company determines in good faith that the Executive’s Disability has occurred during the
term of this Agreement, it will give the Executive written notice of its intention to terminate his employment. For purposes of this Agreement, “Disability” shall mean the Executive’s inability to substantially perform the
essential duties of his job with or without reasonable accommodation on a full-time basis for 180 calendar days during any consecutive twelve-month period or for 90 consecutive days as a result of incapacity due to mental or physical illness.

 (b) DEATH. Automatically on the date of death of the Executive. 

(c) CAUSE. Immediately upon written notice by the Company to the Executive of a termination for Cause. “Cause” shall
mean (i) the Executive’s commission of an act of fraud, embezzlement or theft against the Company or its subsidiaries; (ii) the Executive’s conviction of, or a plea of no contest to, a felony; (iii) willful nonperformance by
the Executive (other than by reason of disability or illness) of his material duties as an employee of the Company, which, to the extent it is curable by the Executive, is not cured within thirty (30) days after written notice thereof is given
to the Executive by the Company; (iv) the Executive’s material breach of this Agreement or any other material agreement between the Executive and the Company or any of its subsidiaries, including the Confidentiality Agreement, which, to
the extent it is curable by the Executive, is not cured within thirty (30) days after written notice thereof is given to the Executive by the Company; or (v) the Executive’s gross negligence, willful misconduct or any other act of
willful disregard for the Company’s or any of its subsidiaries’ best interests, which, to the extent it is curable by the Executive, is not cured within thirty (30) days after written notice thereof is given to the Executive by the
Company. 
 (d) WITHOUT CAUSE. Upon written notice by the Company to the Executive no earlier than eighteen (18) months after
the Effective Date of an involuntary termination without Cause and other than due to death or Disability. 
 (e) GOOD REASON.
“Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following conditions during the Employment Term without the Executive’s express written consent;
provided that any resignation by the Executive due to any of the following conditions shall only be deemed for Good Reason if: (i) the Executive gives the Company written notice of the intent to terminate for Good Reason within
sixty (60) days following the first occurrence of the condition(s) that the Executive believes constitutes Good Reason, which notice shall describe such condition(s); (ii) the Company fails to remedy, if remediable, such condition(s) within
thirty (30) days following receipt of the written notice (the “Cure Period”) of such condition(s) from the Executive; and (iii) the Executive actually resigns his employment within the first thirty (30) days after
expiration of the Cure Period: 
 (1) any material reduction by the Company of the Executive’s Base Salary or Target Bonus as
initially set forth herein or as the same may be increased from time to time; 

  
 4 of 13 

 (2) any material diminution in the Executive’s duties, title, responsibilities or
authority; 
 (3) a requirement that the Executive report to a corporate officer or employee other than the Company’s Chief Executive
Officer, other than any such requirement following a Significant Event (as defined in the Company’s 2013 Share Ownership and Option); 

(4) any material breach of this Agreement, including a breach of the Company’s obligations under Section 4, 5 or
Section 11 (b); or 
 (5) a requirement that the Executive relocate to a principal place of employment more than seventy-five
(75) miles from Mendham, New Jersey. 
 (f) WITHOUT GOOD REASON. The Executive shall provide two (2) weeks’ prior
written notice (the “Transition Period”) to the Company of the Executive’s intended termination of employment without Good Reason (“Voluntary Termination”). During the Transition Period, the Executive shall
assist and advise the Company in any transition of business, customers, prospects, projects and strategic planning, and the Company shall pay the pro rata portion of the Executive’s Base Salary and benefits through the end of the Transition
Period. The Company may, in its sole discretion, upon written notice to the Executive, make such termination of employment effective earlier than the expiration of the Transition Period (“Early Termination Right”), but it shall pay
the pro rata portion of the Executive’s Base Salary and benefits through the earlier of: the end of the Transition Period, or the date that the Executive accepts employment or a consulting engagement from a third party. 

8. CONSEQUENCES OF TERMINATION. Any termination payments made and benefits provided under this Agreement to the
Executive shall be in lieu of any termination or severance payments or benefits for which the Executive may be eligible under any of the plans, policies or programs of the Company or its affiliates as may be in effect from time to time. Subject to
satisfaction of each of the conditions set forth in Section 9, the following amounts and benefits shall be due to the Executive: 
 (a)
DISABILITY. Upon employment termination due to Disability, the Company shall pay or provide the Executive: (i) any unpaid Base Salary through the date of termination and any accrued vacation; (ii) reimbursement for any unreimbursed
expenses owed to Executive; and (iii) all other payments and benefits to which the Executive is entitled under the terms of any applicable compensation arrangement or benefit, equity or other plan or program, including but not limited to any
applicable insurance benefits, payable on the next regularly scheduled Company payroll date following the date of termination or earlier if required by applicable law (collectively, “Accrued Amounts”). In addition, upon the
Executive’s termination due to Disability, the Company shall pay the amounts described in Sections 8(d)(3) and 8(d)(4) to the Executive. 

  
 5 of 13 

 (b) DEATH. In the event the Employment Term ends on account of the Executive’s death,
the Executive’s estate (or to the extent a beneficiary has been designated in accordance with a program, the beneficiary under such program) shall be entitled to any Accrued Amounts, including but not limited to proceeds from any Company
sponsored life insurance programs. In addition, upon the Executive’s death, the Company shall pay the amounts described in Sections 8(d)(3) and 8(d)(4) to the Executive’s estate. 

(c) TERMINATION FOR CAUSE OR WITHOUT GOOD REASON. If the Executive’s employment should be terminated (i) by the Company for
Cause, or (ii) by the Executive without Good Reason, the Company shall pay to the Executive any Accrued Amounts only, and shall not be obligated to make any additional payments to the Executive. 

(d) TERMINATION WITHOUT CAUSE OR FOR GOOD REASON. If the Executive’s employment by the Company is terminated by the Company other
than for Cause (and not due to Disability or death) or by the Executive for Good Reason, other than in circumstances described in Section 8(e), then the Company shall pay or provide the Executive with the Accrued Amounts and subject to
compliance with Section 10: 
 (1) continued payment of the Executive’s Base Salary as in effect immediately preceding the last
day of the Employment Term for a period of twelve (12) months following the termination date (the “Salary Severance Period”) in accordance with the Company’s ordinary payroll practices (for purposes of calculating the
Executive’s severance benefits, the Executive’s Base Salary shall be calculated based on the rate in effect prior to any material reduction in Base Salary that would give the Executive the right to resign for Good Reason (as provided in
Section 7(e)(1))); 
 (2) if the Executive timely elects continued coverage under COBRA for himself and his covered dependents under
the Company’s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue the Executive’s and his covered dependents’ health insurance coverage in effect on the termination date
until the earliest of (i) twelve (12) months following the termination date (the “COBRA Severance Period”); (ii) the date when the Executive becomes eligible for substantially equivalent health insurance coverage in connection
with new employment or; or (iii) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (i)-(iii), the “COBRA
Payment Period”). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on the Executive’s behalf would result in a violation of applicable law (including but not limited to the 2010
Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section 8(d)(2), the Company shall pay the Executive on the last day of
each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding (such amount, the “Special Severance Payment”), such Special Severance
Payment to be made without regard to the Executive’s payment of COBRA premiums. Nothing in this Agreement shall deprive the Executive of his rights under COBRA or ERISA for benefits under plans and policies arising under his employment by the
Company. 

  
 6 of 13 

 (3) in the event that the Executive’s employment is terminated after December 31 of
any performance year, but prior to the Annual Bonus payment date for such performance year, the Executive shall receive: (i) the amount of the Annual Bonus as determined by the Board in good faith for the performance year immediately prior to
the year in which the Executive’s termination occurs if the Company has not determined the amount of the Executive’s Annual Bonus as of the date of the Executive’s termination; or (ii) the amount of the Annual Bonus as already
determined by the Board in good faith for the performance year immediately prior to the year in which the Executive’s termination occurs if the Company has already determined the amount of the Executive’s Annual Bonus as of the date of the
Executive’s termination, payable in either case as a lump sum at the same time annual bonuses are paid to the Company’s executives generally, but no later than March 15 of the calendar year immediately following the calendar year in
which the Annual Bonus is being measured; 
 (4) in the event that the Executive’s employment is terminated: (i) on or before the
date Annual Bonus performance goals are established for the performance year in which the Executive’s termination occurs, the Executive shall receive a pro-rata portion of the Executive’s Target
Bonus for the performance year in which the Executive’s termination occurs, with such pro-rata portion calculated based upon the number of days that the Executive was employed during such performance year
divided by the total number of days in such performance year; or (ii) after the date Annual Bonus performance goals are established for the performance year in which the Executive’s termination occurs (but on or before December 31 of
such performance year), the Executive shall receive a pro-rata portion of the Executive’s Target Bonus for the performance year in which the Executive’s termination occurs, with such pro-rata portion calculated based upon the Executive’s achievement of performance goals as determined by the Board in good faith, payable in either case as a lump sum payment on the Company’s first
ordinary payroll date occurring on or after the General Release effective date (namely, the date it can no longer be revoked) or as soon thereafter as is reasonable practicable thereafter; and 

(e) TERMINATION WITHOUT CAUSE OR FOR GOOD REASON FOLLOWING A SIGNIFICANT EVENT. If the Executive’s employment by the Company is
terminated by the Company other than for Cause (and not due to Disability or death), or by the Executive for Good Reason, in either case on or within twenty-four (24) months immediately following a Significant Event, then the Company shall pay
or provide the Executive with the Accrued Amounts and all of the benefits described in Section 8(d) above, subject to compliance with Section 10; provided that: (i) the Salary Severance Period defined in
Section 8(d)(1) shall be increased to a total of eighteen (18) months following the termination date; (ii) the COBRA Severance Period defined in Section 8(d)(2) shall be increased to a total of eighteen (18) months following
the termination date; and (iii) in lieu of the pro-rata bonus described in Section 8(d)(4), the Company shall pay the Executive the full Target Bonus for the performance year in which the
Executive’s termination occurs, payable as a lump sum payment on the Company’s first ordinary payroll date occurring on or after the General Release effective date (namely, the date it can no longer be revoked). 

9. CONDITIONS. Any payments or benefits made or provided pursuant to Section 8 (other than Accrued Amounts) are subject to
the Executive’s (or, in the event of the Executive’s death, the beneficiary’s or estate’s, or in the event of the Executive’s Disability, the guardian’s): 

(a) compliance with the provisions of Section 10 hereof; 

  
 7 of 13 

 (b) delivery to the Company of the executed Agreement and General Release (the “General
Release”), which shall be in the form attached hereto as Appendix A (with such changes therein or additions thereto as needed under then applicable law to give effect to its intent and purpose) within 21 days following the date of
termination of employment, and permitting the General Release to become effective in accordance with its terms; and 
 (c) delivery to the
Company of a resignation from all offices, directorships and fiduciary positions with the Company, its affiliates and employee benefit plans, by no later than 90 days following termination of employment. 

Notwithstanding the due date of any post-employment payments, any amounts due following a termination under this Agreement (other than Accrued
Amounts) shall not be due until after the expiration of any revocation period applicable to the General Release without the Executive having revoked such General Release, and any such amounts shall be paid or commence being paid to the Executive on
the Company’s first ordinary payroll date occurring on or after the expiration of such revocation period without the occurrence of a revocation by the Executive (or such later date as may be required under Section 17 or the final sentence
of this Section 9). Nevertheless (and regardless of whether the General Release has been executed by the Executive), upon any termination of Executive’s employment, Executive shall be entitled to receive any Accrued
Amounts, payable after the date of termination in accordance with the Company’s applicable plan, program, policy or payroll procedures. Notwithstanding anything to the contrary in this Agreement, if any severance pay or benefits are deferred
compensation under Section 409A (as defined below), and the period during which the Executive may sign the General Release begins in one calendar year and ends in another, then the severance pay or benefit shall not be paid or the first payment
shall not occur until the later calendar year. 
 10. CONFIDENTIALITY AND POST-EMPLOYMENT OBLIGATIONS. As a condition of
employment, the Executive agrees to execute and abide by the Company’s current form of Confidentiality and Non-Competition Agreement
(“Confidentiality Agreement”), which may be amended by the parties from time to time without regard to this Agreement. The Confidentiality Agreement contains provisions that are intended by the parties to survive and do
survive termination of this Agreement. 
 11. ASSIGNMENT. 

(a) The Executive may not assign or delegate any rights or obligations hereunder without first obtaining the written consent of the Company.

 (b) This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives.
The Company will require any acquirer or successor of the Company in any merger, consolidation, sale, or acquisition of the Company, or a similar transaction to assume the Company’s obligations under this Agreement, and any failure to do so
shall constitute a material breach of this Agreement. 
 12. NOTICE. For the purpose of this Agreement, notices and all other
communications provided for in this Agreement shall be in writing and shall be deemed to have 

  
 8 of 13 

 
been duly given (a) on the date of delivery if delivered by hand, (b) on the date of transmission, if delivered by confirmed facsimile, (c) on the first business day following the
date of deposit if delivered by guaranteed overnight delivery service, or (d) on the fourth business day following the date delivered or mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed
as follows: If to the Executive: at the address (or to the facsimile number) shown on the records of the Company. 
 If to the Company: 

Eloxx Pharmaceuticals, Inc. 
 950
Winter Street 
 Waltham, MA 02451 
 or to such
other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. 

13. SECTION HEADINGS; INCONSISTENCY. The section headings used in this Agreement are included solely for convenience and shall
not affect, or be used in connection with, the interpretation of this Agreement. If there is any inconsistency between this Agreement and any other agreement plan, program, policy or practice (collectively, “Other Provision”) of the
Company the terms of this Agreement shall control over such Other Provision. 
 14. SEVERABILITY. The provisions of this
Agreement shall be deemed severable and the invalidity of unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. 

15. COUNTERPARTS. This Agreement may be executed in counterparts, each of which shall be deemed to be an original but all of
which together will constitute one and the same instruments. One or more counterparts of this Agreement may be delivered by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart
thereof. 
 16. MISCELLANEOUS. No provision of this Agreement may be modified, waived or discharged unless such waiver,
modification or discharge is agreed to in writing and signed by the Executive and such officer or director of the Company as may be designated or authorized by the Board. No waiver by either party hereto at any time of any breach by the other party
hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement
together with all exhibits hereto and the Confidentiality Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein. No agreements or representations, oral or otherwise, express or implied,
with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the
Commonwealth of Massachusetts without regard to its conflicts of law principles. 

  
 9 of 13 

 17. SECTION 409A. 

(a) Notwithstanding anything to the contrary herein, the following provisions apply to the extent severance benefits provided herein are
subject to Section 409A of Code and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”). Severance benefits payable upon a termination of employment
shall not commence until Executive has a “separation from service” for purposes of Section 409A. Each installment of severance benefits is a separate “payment” for purposes of Treas. Reg.
Section 1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are not available and Executive is, upon separation from
service, a “specified employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the severance benefits shall be delayed until the
earlier of (i) six (6) months and one day after Executive’s separation from service, or (ii) Executive’s death. Any payment or benefit otherwise payable or to be provided in the six (6) month period following separation from
service that is not so paid or provided by reason of this Section 17 shall be accumulated and paid or provided in a single lump sum, as soon as practicable (and in all events within 15 days) after the date that is six (6) months after
Executive’s separation from service (or, if earlier, as soon as practicable, and in all events within 15 days, after the date of Executive’s death) 

(b) It is intended that this Agreement shall comply with the requirements of Section 409A, and any ambiguity contained herein shall be
interpreted in such manner so as to avoid adverse personal tax consequences under Section 409A. Notwithstanding the foregoing, the Company shall in no event be obligated to indemnify the Executive for any taxes or interest that may be assessed
by the IRS pursuant to Section 409A of the Code on payments made pursuant to this Agreement. 
 18. MITIGATION OF
DAMAGES. In no event shall the Executive be obliged to seek other employment or take any other action by way of mitigation of the severance benefits payable to the Executive under any of the provisions of this Agreement, nor shall the amount
of any severance benefit hereunder be reduced by any compensation earned by the Executive as a result of employment by another employer, except as set forth in this Agreement. 

19. REPRESENTATIONS. The Executive represents and warrants to the Company that the Executive has the legal right to enter into
this Agreement and to perform all of the obligations on the Executive’s part to be performed hereunder in accordance with its terms and that the Executive is not a party to any agreement or understanding, written or oral, which could prevent
the Executive from entering into this Agreement or performing all of the Executive’s obligations hereunder. The Executive further represents and warrants that he has been advised to consult with an attorney and that he has been represented by
the attorney of his choosing during the negotiation of this Agreement (or chosen not to be so represented), that he has consulted with his attorney before executing this Agreement (or chosen not to consult an attorney), that he has carefully read
and fully understand all of the provisions of this Agreement and that he is voluntarily entering into this Agreement. 

  
 10 of 13 

 20. NON-DISPARAGEMENT. Both during and
after the Employment Term, the Executive and the Company (through its officers and directors) agree not to disparage the other party, and the other party’s officers, directors, employees, shareholders, affiliates and agents, in any manner
likely to be harmful to them or their business, business reputation or personal reputation; provided that both the Executive and the Company may respond accurately and fully to any question, inquiry or request for information when
required by legal process and provided further that nothing in this Section 20 shall preclude any party from making truthful statements that are reasonably necessary or to enforce or defend the party’s rights under this Agreement. 

21. WITHHOLDING. The Company may withhold from any and all amounts payable under this Agreement such federal, state and local
taxes as may be required to be withheld pursuant to any applicable law or regulation. 
 22. SURVIVAL. The respective
obligations of, and benefits afforded to, the Company and the Executive which by their express terms or clear intent survive termination of the Executive’s employment with the Company, including, without limitation, the provisions of Sections 8
through 24, inclusive, of this Agreement, will survive termination of the Executive’s employment with the Company, and will remain in full force and effect according to their terms. 

23. AGREEMENT OF THE PARTIES. The language used in this Agreement will be deemed to be the language chosen by the parties hereto
to express their mutual intent. Neither the Executive nor the Company shall be entitled to any presumption in connection with any determination made hereunder in connection with any arbitration, judicial or administrative proceeding relating to or
arising under this Agreement. 
 24. DISPUTE RESOLUTION. In the event of any controversy, dispute or claim between the parties
under, arising out of or related to this Agreement (including but not limited to, claims relating to breach, termination of this Agreement, or the performance of a party under this Agreement) whether based on contract, tort, statute or other legal
theory (collectively referred to hereinafter as “Disputes”), the parties shall follow the dispute resolution procedures set forth below. Any Dispute shall be finally settled by arbitration in accordance with the Employment
Arbitration Rules & Procedures of JAMS (“JAMS”) then in force, and that the arbitration hearings shall be held in Boston, Massachusetts. The parties agree to (i) appoint an arbitrator who is knowledgeable in employment
and human resource matters and, to the extent possible, the industry in which the Company operates, and instruct the arbitrator to follow substantive rules of law; (ii) require the testimony to be transcribed; and (iii) require the award
to be accompanied by findings of fact and a statement of reasons for the decision. The arbitrator shall have the authority to permit discovery, to the extent deemed appropriate by the arbitrator, upon request of a party, but such discovery process
shall continue for no more than thirty (30) days. The arbitrator shall have no power or authority to add to or detract from the written agreement of the parties. If the parties cannot agree upon an arbitrator within ten (10) days after
demand by either of them, either or both parties may request JAMS name a panel of five (5) arbitrators. The Company shall strike the names of two (2) off this list; then, the Executive shall strike two (2) of the remaining names; and
the remaining name shall be the arbitrator. In the event that arbitration results in losing and wining parties, the losing party shall pay for all attorneys’ fees and expenses and the JAMS fees and expenses. Any award shall be final, binding
and conclusive upon the parties and a judgment rendered thereon may be entered in any court 

  
 11 of 13 

 
having jurisdiction thereof. This Section shall not limit the right of any party to sue for injunctive relief for a breach of the obligations of this Agreement. 

[signature page follows] 

  
 12 of 13 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, effective as of the date
first written above. 
  

			
	ELOXX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Robert Ward

		 	Robert Ward
		 	Its: Chief Executive Officer and Director
	
	EXECUTIVE
		
		 	 /s/ Gregory C. Williams

		 	Gregory C. Williams

  
 13 of 13 

 APPENDIX A 

FORM OF RELEASE 

AGREEMENT AND GENERAL RELEASE 

Eloxx Pharmaceuticals, Inc. (the “Company”) and Gregory C. Williams (“Executive”) agree: 

1. Last Day of Employment. Executive’s last day of employment with Employer was [INSERT DATE] (the
“Termination Date”). In addition, effective as of the Termination Date, Executive ceased to serve as the General Counsel of the Company and its affiliates and ceased to be eligible for any benefits or compensation
from the Company and its affiliates other than as specifically provided in Section 8 of the Executive Employment Agreement between the Company and Executive dated as of [DATE] (the “Employment Agreement”). Executive further
acknowledges and agrees that from and after the date Executive executes this Agreement and General Release, Executive will not represent (and since the Termination Date the Executive has not represented) the Executive as being a director, employee,
officer, trustee, agent or representative of the Company or its affiliates for any purpose. In addition, effective as of Termination Date, Executive resigns from all offices, directorships, trusteeships, committee memberships and fiduciary
capacities held with, or on behalf of, the Company and its affiliates or any benefit plans of the Company and its affiliates. These resignations will become irrevocable as set forth in Section 3 below. 

2. Consideration. The parties acknowledge that this Agreement and General Release is being executed in accordance with Section 9
of the Employment Agreement. 
 3. Revocation. Executive may revoke this Agreement and General Release for a period of seven
(7) calendar days following the day Executive executes this Agreement and General Release. Any revocation within this period must be submitted in writing to the Company and state, “I hereby revoke my acceptance of our Agreement and General
Release.” The revocation must be delivered to the Chairman of the Board, Eloxx Pharmaceuticals Ltd., 950 Winter Street, Waltham, MA 02451, or his designee by an overnight delivery service. This Agreement and General Release shall become
effective and irrevocable on the eighth (8th) day after Executive executes it, unless earlier revoked by Executive in accordance with this Section 3 (the “Effective Date”). 

4. General Release of Claims. (A) Executive and the Executive’s heirs, executors, administrators, successors and assigns
(collectively referred to throughout this Agreement as “Employee”) knowingly and voluntarily release and forever discharge the Company and its affiliates, subsidiaries, divisions, benefit plans, successors and assigns in such
capacity, and the current, future and former employees, officers, directors, trustees and agents thereof (collectively referred to as “Employer”) from any and all actions, causes of action, contributions, indemnities, duties, debts,
sums of money, suits, controversies, restitutions, understandings, agreements, promises, claims regarding stock, stock options or other forms of equity compensation, commitments, damages, fees and liabilities, responsibilities and any and all
claims, demands, executions and liabilities of whatsoever kind, nature or description, oral or written, known or 

  
 1 of 5 

 
unknown, matured or unmatured, suspected or unsuspected at the present time, in law or in equity, whether known and unknown, against Employer, which the Employee has, has ever had or may have as
of the date of Executive’s execution of this Agreement and General Release, including, but not limited to, any alleged violation of: 
  

	 	•	 	Title VII of the Civil Rights Act of 1964, as amended; 

  

	 	•	 	The Civil Rights Act of 1991; 

  

	 	•	 	Sections 1981 through 1988 of Title 42 of the United States Code, as amended; 

  

	 	•	 	The Employee Retirement Income Security Act of 1974, as amended; 

  

	 	•	 	The Immigration Reform and Control Act, as amended; 

  

	 	•	 	The Americans with Disabilities Act of 1990, as amended; 

  

	 	•	 	The Age Discrimination in Employment Act of 1967, as amended; 

  

	 	•	 	The Older Workers Benefit Protection Act of 1990; 

  

	 	•	 	The Worker Adjustment and Retraining Notification Act, as amended; 

  

	 	•	 	The Occupational Safety and Health Act, as amended; 

  

	 	•	 	The Family and Medical Leave Act of 1993; 

  

	 	•	 	The Massachusetts Wage Act; 

  

	 	•	 	Massachusetts anti-discrimination laws, M.G.L Chapter 151B-Any wage payment and collection, equal pay and other similar laws, acts and statutes of the Commonwealth of Massachusetts or the United States;

  

	 	•	 	Any other federal, state or local civil or human rights law or any other local, state or federal law, regulation or ordinance; 

  

	 	•	 	Any public policy, contract, tort, or common law; or 

  

	 	•	 	Any allegation for costs, fees, or other expenses including attorneys’ fees incurred in these matters. 

Notwithstanding anything herein to the contrary, the sole matters to which the Agreement and General Release do not apply are:
(i) Employee’s express rights or claims for accrued vested benefits under any employee benefit plan, policy or arrangement maintained by Employer or under COBRA; (ii) Employee’s rights under the provisions of the Employment
Agreement which are intended to survive termination of employment; ; or (iii) any rights of the Executive to indemnification as a Director or Officer of the Company. 

  
 2 of 5 

 5. No Claims Permitted. Employee waives Executive’s right to file any charge or
complaint against Employer arising out of Executive’s employment with or separation from Employer before any federal, state or local court or any state or local administrative agency, except where such waivers are prohibited by law (with the
understanding that that this Agreement and General Release bars the Executive from recovering monetary relief from Employer in connection with any charges or complaints which are not waived hereunder). 

Furthermore, nothing in this Agreement or General Release and Waiver of Claims prohibits Executive from reporting possible violations of
federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are
protected under the whistleblower provisions of federal law or regulation. Executive does not need the prior authorization of the Company to make any such reports or disclosures and Executive is not required to notify the Company that Executive has
made such reports or disclosures. 
 6. Affirmations. Employee affirms Executive has not filed, has not caused to be filed, and is
not presently a party to, any claim, complaint, or action against Employer in any forum. Employee further affirms that the Executive has been paid and/or has received all compensation, wages, bonuses, commissions, and/or benefits to which Executive
may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to Executive, except as provided in Section 8 of the Employment Agreement. Employee also affirms Executive has no known workplace injuries. 

7. Cooperation; Return of Property. Employee agrees to reasonably cooperate with Employer and its counsel in connection with any
investigation, administrative proceeding or litigation relating to any matter that occurred during Executive’s employment in which Executive was involved or of which Executive has knowledge. Employer will reimburse the Employee for any
reasonable out-of-pocket travel, delivery or similar expenses incurred in providing such service to Employer. Employee represents that Employee has returned to Employer
all property belonging to Employer, including but not limited to any leased vehicle, laptop, cell phone, keys, access cards, phone cards and credit cards, provided that Executive may retain, and Employer shall cooperate in transferring,
Executive’s cell phone number and Executive’s personal rolodex and other address books. 
 8. Governing Law and
Interpretation. This Agreement and General Release shall be governed and conformed in accordance with the laws of the Commonwealth of Massachusetts without regard to its conflict of laws provisions. In the event Employee or Employer breaches any
provision of this Agreement and General Release, Employee and Employer affirm either may institute an action to specifically enforce any term or terms of this Agreement and General Release. Should any provision of this Agreement and General Release
be declared illegal or unenforceable by any court of competent jurisdiction and should the provision be incapable of being modified to be enforceable, such provision shall immediately become null and void, leaving the remainder of this Agreement and
General Release in full force and effect. Nothing herein, however, shall operate to void or nullify any general release language contained in the Agreement and General Release. 

  
 3 of 5 

 9. No Admission of Wrongdoing. Employee agrees neither this Agreement and General Release
nor the furnishing of the consideration for this Agreement and General Release shall be deemed or construed at any time for any purpose as an admission by Employer of any liability or unlawful conduct of any kind. 

10. Non-Disparagement. Employee and Employer (through its officers and directors) agree not to
disparage the other party, and the other party’s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both
Employee and Employer may respond accurately and fully to any question, inquiry or request for information when required by legal process and provided further that nothing in this Section 10 shall preclude Employer or Employee
from making truthful statements that are reasonably necessary or to enforce or defend the party’s rights under this Agreement and General Release. 

11. Amendment. This Agreement and General Release may not be modified, altered or changed except upon express written consent of both
parties wherein specific reference is made to this Agreement and General Release. 
 12. Entire Agreement. This Agreement and General
Release and the Confidentiality Agreement (as defined in the Employment Agreement) sets forth the entire agreement between the parties hereto and fully supersedes any prior agreements or understandings between the parties; provided,
however, that notwithstanding anything in this Agreement and General Release, the provisions in the Employment Agreement which are intended to survive termination of the Employment Agreement, including but not limited to those contained in
Section 10 thereof, shall survive and continue in full force and effect. Employee acknowledges Executive has not relied on any representations, promises, or agreements of any kind made to Executive in connection with Executive’s decision
to accept this Agreement and General Release. 
 13. ADEA. Employee understands and acknowledges that Employee is waiving and
releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is knowing and voluntary. Employee understands and agrees that this waiver and release does
not apply to any rights or claims that may arise under the ADEA after the date Executive signs this Agreement and General Release. Employee understands and acknowledges that the consideration given for this waiver and release is in addition to
anything of value to which Employee was already entitled. Employee further understands and acknowledges that Employee has been advised by this writing that nothing in this Agreement prevents or precludes Executive from challenging or seeking a
determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. 

[signature page follows] 

  
 4 of 5 

 EMPLOYEE HAS BEEN ADVISED THAT EXECUTIVE HAS UP TO
TWENTY-ONE (21) CALENDAR DAYS TO REVIEW THIS AGREEMENT AND GENERAL RELEASE AND HAS BEEN ADVISED IN WRITING TO CONSULT WITH AN ATTORNEY PRIOR TO EXECUTION OF THIS AGREEMENT AND GENERAL RELEASE. 

EMPLOYEE AGREES ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS AGREEMENT AND GENERAL RELEASE DO NOT RESTART OR AFFECT IN ANY MANNER
THE ORIGINAL TWENTY-ONE (21) CALENDAR DAY CONSIDERATION PERIOD. IN THE EVENT EMPLOYEE SIGNS THIS AGREEMENT AND GENERAL RELEASE AND RETURNS IT TO THE COMPANY IN LESS THAN THE
TWENTY-ONE (21) DAY PERIOD IDENTIFIED ABOVE, EMPLOYEE HEREBY ACKNOWLEDGES THAT EMPLOYEE HAS FREELY AND VOLUNTARILY CHOSEN TO WAIVE THE TIME PERIOD ALLOTTED FOR CONSIDERING THIS AGREEMENT AND GENERAL
RELEASE. 
 HAVING ELECTED TO EXECUTE THIS AGREEMENT AND GENERAL RELEASE, TO FULFILL THE PROMISES SET FORTH HEREIN, AND TO RECEIVE THE SUMS
AND BENEFITS SET FORTH IN THE EMPLOYMENT AGREEMENT, EMPLOYEE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS AGREEMENT AND GENERAL RELEASE INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS EXECUTIVE HAS OR MIGHT HAVE AGAINST
EMPLOYER. 
 IN WITNESS WHEREOF, the parties hereto knowingly and voluntarily executed this Agreement and General Release as of the date set
forth below: 
  

					
	ELOXX PHARMACEUTICALS, INC.

 
					
		
	By:	 	  

		 	Name:	 	
		 	Its:	 	
			
		 	Date:	 	

 
					
	
	EXECUTIVE
	
	  

Gregory C. Williams

	
	Date:

  
 5 of 5bsqr-ex101_6.htm

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

Exhibit 10.1

Bsquare Corporation

Board Observer and Standstill Agreement

 

This Board Observer Agreement (the “Agreement”) is made effective as of June 25, 2018 (“Effective Date”) by and between: 

 

	
 
	
(i)
	
Bsquare Corporation, a Washington corporation with offices at 110 – 110th Avenue NE #300, Bellevue, WA 98004 (the “Company”), and 

 

	
 
	
(ii)
	
Each of Palogic Value Fund, L.P., Palogic Value Management, L.P., and Palogic Capital Management, LLC (collectively, “PCM”).

 

WHEREAS, the Company desires to provide to PCM, a shareholder of the Company, with certain observation rights regarding the Company’s board of directors (the “Board”), as further described, and subject to the terms and conditions set forth, herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.Observer Rights.

 

	
 
	
1.1
	
Subject to the terms and conditions of this Agreement, the Company grants to PCM the option and right to appoint one (1) representative (the “Observer”) to attend all meetings (including telephonic or videoconference meetings of the Board in a non-voting, observer capacity; provided that any such representative shall have executed and delivered to the Company a copy of the Acknowledgement and Agreement to be Bound in the form attached hereto as Exhibit A (the “Acknowledgement”). The Company shall have the right, in its reasonable discretion, to approve or reject any person who is to be appointed by PCM to serve as an Observer hereunder.  Except as otherwise set forth herein, the Observer may participate fully in discussions of all matters brought to the Board  for consideration, but in no event shall the Observer (i) be deemed to be a member of the Board; (ii) without limitation of the obligations expressly set forth in this Agreement or the Acknowledgement, have or be deemed to have, or otherwise be subject to, any duties (fiduciary or otherwise) to the Company or its shareholders; or (iii) have the right to propose or offer any motions or resolutions to the Board . Upon request, the Company shall allow the Observer to attend Board meetings by telephone or electronic communication. The presence of the Observer shall not be required for purposes of establishing a quorum.

 

	
 
	
1.2
	
The Company shall provide to the Observer copies of all notices, minutes, consents and other materials that it provides to Board members (collectively, “Board Materials”), including any draft versions, proposed written consents, and exhibits and annexes to any such materials, at the same time and in the same manner as such information is delivered to the Board members.

 

	
 
	
1.3
	
Notwithstanding anything herein to the contrary, the Company may exclude the Observer from access to any Board Materials, meeting or portion thereof if the Board concludes, acting in good faith, that (i) such exclusion is reasonably necessary to preserve the 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

	
 
		
attorney-client or work product privilege between the Company and its counsel; (ii) such Board Materials or discussion relates to the Company’s relationship, contractual or otherwise, with PCM or its affiliates or any actual or potential transactions between or involving the Company and PCM; or (iii) such exclusion is necessary to avoid a conflict of interest or disclosure that is restricted by any agreement to which the Company is a party or otherwise bound.

 

2.Confidential Information. PCM agrees that each Observer shall execute a Nondisclosure Agreement in the form attached hereto as Exhibit B (the “Observer NDA”).  The Observer NDA and the PCM NDA (as defined in Section 6.4 below) are incorporated herein by reference in their entirety.  If the Observer NDA and/or the PCM NDA expires by their terms prior to a Termination (as defined below), each of the Observer and PCM agrees to continue to abide by all of the terms of the Observer NDA and the PCM NDA, as applicable (as if such agreements remained in effect), through the date of Termination and for period of three (3) years following any Termination. 

 

3.Expenses. PCM and/or the Observer shall be responsible for any and all out-of-pocket expenses incurred in connection with the Observer’s attendance at Board meetings.

 

4.Standstill and Related Obligations. PCM agrees that during the term of this Agreement and for period of three (3) years following any Termination (the “Standstill Period”), unless otherwise consented to in writing by the Company in advance, PCM will not in any manner, directly or indirectly:

 

	
 
	
(a)
	
effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect, any acquisition of any securities (or beneficial ownership thereof) of the Company or any of its subsidiaries, if after any such acquisition PCM holds, beneficially or of record, directly or indirectly, in excess of fifteen percent (15%) of the total outstanding common stock of the Company; or

 

	
 
	
(b)
	
 enter into any discussions or arrangements with any third party with respect to any actions covered by clause (a).

 

For clarification, nothing in this Section 4 shall restrict PCM from making any offer or proposal to the Company on a confidential basis so long as such offer or proposal does not require the Company to make a public announcement regarding such offer or proposal or any of the types of matters described in this Section 4.

 

The Company confirms that the Board has previously approved in advance, solely for purposes of RCW 23B.19.040(1)(a)(ii), any future acquisition by PCM of shares of the Company’s common stock that would result in PCM becoming an “acquiring person” as defined in RCW 23B.19.020(1) (defined as beneficially owning in the aggregate total outstanding shares of the Company’s common stock comprising 10% or more of the voting power of the Company).  The Company agrees that such approval shall not be withdrawn and shall remain effective at least until the termination of the Standstill Period.

 

5.Notices. Notices must be in writing and delivered to each party at their respective addresses set forth below, or to such other address as may be given by each party from time to time under this Section. Notices shall be deemed properly given upon personal delivery, the day following deposit by overnight carrier, or three (3) days after deposit in the U.S. mail.

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

		
		
	
Bsquare Corporation
	
Palogic Value Fund, L.P.

Palogic Value Management, L.P.

Palogic Capital Management, LLC

	
110 – 110th Avenue NE, Suite 300

Bellevue, WA 98004

 

Attn: General Counsel and VP, Legal
	
5310 Harvest Hill Road, Suite 110 

Dallas, TX 75230

 

Attn: Ryan Vardeman

 

6.Remedies: Injunctive Relief. The Company, on the one hand, and PCM, on the other hand, each acknowledge and agree that monetary damages would not be a sufficient remedy for any breach (or threatened breach) of this Agreement by it and that, in the event of any breach or threatened breach hereof, (a) the non-breaching party shall have the right to immediate injunctive and other equitable relief, without proof of actual damages; (b) the breaching party will not plead in defense thereto that there would be an adequate remedy at law; and (c) the breaching party agrees to waive any applicable right or requirement that a bond be posted by the non-breaching party. Such remedies will not be the exclusive remedies for a breach of this Agreement, but rather will be in addition to all other remedies that may be available to the non-breaching party at law or in equity. In the event that either party institutes any legal suit, action or proceeding against the other party arising out of or relating to this Agreement, the prevailing party in the suit, action or proceeding shall be entitled to receive, in addition to all other damages to which it may be entitled, the costs incurred by such party in conducting the suit, action or proceeding, including reasonable attorneys’ fees and expenses and court costs.

 

7.Applicable Law; Venue. This Agreement, and any and all claims, controversies and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort or statute, shall be governed by the laws of Washington, including its statutes of limitations, without giving effect to any conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. Each party (a) irrevocably and unconditionally consents to the personal jurisdiction and venue of the courts located in King County, Washington; (b) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; (c) agrees that it shall not bring any action relating to this Agreement or otherwise in any court other than the courts located in King County, Washington or in the United States District Court for the Western District of Washington; and (d) irrevocably waives the right to trial by jury.

 

8.Termination. In the event that the percentage of the outstanding common stock of the Company beneficially held by PCM decreases materially from the percentage that PCM holds as of the Effective Date, then the Company may terminate this Agreement at any time thereafter upon written notice to PCM.  PCM may terminate this Agreement at any time upon written notice to the Company.  Any such termination of this Agreement shall be referred to herein as a “Termination.”  Sections 2, 4, 6, 7 and 8 shall survive any such Termination.

 

9.Miscellaneous Provisions. 

 

9.1Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision. Solely to the extent that any provisions or restrictions in this Agreement is found by a court to be unreasonable or unenforceable, then such court may amend or modify any such provision or restriction so it can be enforced to the fullest extent permitted by law. 

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

9.2Headings and eSignature. The section headings in this Agreement have been inserted as a matter of convenience of reference and are not a part of this Agreement. This Agreement may be executed by electronic signature in any number of counterparts, each of which together shall constitute one and the same instrument. 

 

9.3No Waivers. Any waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a party to insist on strict adherence to any term of this Agreement on one or more occasions shall not be construed as a waiver or deprive such party of the right to thereafter insist on strict adherence to that term or any other term of this Agreement.

 

9.4Entire Agreement; No Assignment. This Agreement, together with Observer NDA and the Mutual Nondisclosure Agreement entered into as of June 25, 2018 (“PCM NDA”), which are incorporated herein by this reference, constitutes the entire agreement and understanding of the parties, and supersedes any and all previous agreements and understandings, whether oral or written, between the parties regarding the matters set out in this Agreement. No provision of this Agreement may be amended, modified or waived, except in a writing signed by the parties hereto. This Agreement may not be assigned by PCM.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

 

		
	
Palogic Value Fund, L.P. (“PCM”)
	
Bsquare Corporation 

	
By: /s/ Ryan Vardeman            

Name: Ryan Vardeman           

Title: Sole Member of Palogic Capital Management, LLC                 
Palogic Value Management, L.P. (“PCM”)By: /s/ Ryan Vardeman            Name: Ryan Vardeman           Title: Sole Member of Palogic CapitalManagement, LLC                 Palogic Capital Management, LLC (“PCM”)By: /s/ Ryan Vardeman            Name: Ryan Vardeman           Title: Sole Member of Palogic Capital Management, LLC
 
	
By:  /s/ Andrew Harries                 

Name:  Andrew Harries              

Title:  Executive Chair, Board of Directors  

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

EXHIBIT A

ACKNOWLEDGEMENT AND AGREEMENT TO BE BOUND

 

June 25, 2018

This Acknowledgement and Agreement to be Bound (”Acknowledgement”) is given by the undersigned as a representative designated by PCM to act as the Observer pursuant to that certain Board Observer Agreement by and between Bsquare Corporation (the “Company”) and PCM dated as of June 25, 2018 (the “Agreement”). Capitalized terms used, but not defined, herein have the meanings ascribed thereto in the Agreement.

1.By executing this Acknowledgement, the undersigned acknowledges and agrees as follows:

 

	
 
	
(a)
	
That he has received and reviewed a copy of the Agreement and that his execution of this Acknowledgement is a condition precedent to his appointment as the Observer under the Agreement.

 

	
 
	
(b)
	
To execute and deliver the Observer NDA and to treat any Confidential Information obtained by him from the Company (or any director, officer, employee or agent thereof) in accordance with the Observer NDA and consistent with the Observer’s and PCM’s obligations under Section 2 of the Agreement.

 

	
 
	
(c)
	
That either the Company, PCM or the undersigned may terminate the undersigned’s service as the Observer, with or without cause, in accordance with the terms of the Agreement. If the undersigned ceases to serve as the Observer, he shall (a) no longer be entitled to exercise any rights afforded to the Observer under Section 1 of the Agreement and (b) as promptly as practicable (but in any event not later than three (3) business days thereafter) deliver all physical materials containing or consisting of Confidential Information in his possession or control to PCM.

 

2.Upon the written request of the Company or PCM, the undersigned will promptly execute and deliver any and all further instruments and documents and take such further action as such party deems necessary to effect the purposes of this Acknowledgement.

 

3.No provision of this Acknowledgement may be amended, modified or waived, except in a writing signed by the undersigned, the Company and PCM. The invalidity or unenforceability of any provision of this Acknowledgement shall not affect the validity or enforceability of any other provision, and if any restriction in this Acknowledgement is found by a court to be unreasonable or unenforceable, then such court may amend or modify the restriction so it can be enforced to the fullest extent permitted by law. This Acknowledgement may be executed by electronic signature in any number of counterparts, each of which together shall constitute one and the same instrument.

 

4.  The undersigned acknowledges and agrees that monetary damages would not be a sufficient remedy for any breach (or threatened breach) of this Agreement by him and that, in the event of any breach or threatened breach hereof, (a) the Company shall have the right to immediate injunctive and other equitable relief, without proof of actual damages; (b) he will not plead in defense thereto that there would be an adequate remedy at law, and (c) he agrees to waive any applicable right or requirement that a bond be posted by the Company. Such remedies will not be the exclusive remedies for a breach of this Agreement, but will be in addition to all other remedies that may be available to the Company at law or in equity.

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

 

5.Section 9(Applicable Law; Venue) of the Agreement shall be applicable to this Acknowledgement, and the undersigned hereby agrees to be bound thereby, as if set forth herein. If any notice, request, demand or other communication is given to the undersigned under this Acknowledgement, it shall be given to him at his address set forth on the signature page hereto or such other address as the undersigned shall have provided in writing to the Company and PCM in accordance with Section 5 of the Agreement.

 

IN WITNESS WHEREOF, the undersigned has executed this Acknowledgement as of the date first above written.

		
	
 
	
 

	
 

 
	
   /s/ Robert Peters                         

Robert Peters

Principal, Palogic Value Management, L.P.

5310 Harvest Hill Road, Suite 110 

Dallas, TX 75230

 

ACKNOWLEDGED AND ACCEPTED as of this 25th day of June, 2018:

	
	
Bsquare Corporation

	
Signed:   /s/ Andrew Harries                        

Name: Andrew Harries                           

Title:  Executive Chairman of the Board of Directors

 

	
 

	
 

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	

 

		
	
Bsquare Corporation Board Observer and Standstill Agreement
	
 

	
 

 

EXHIBIT B

Form of Nondisclosure Agreement

		
	
Bsquare Corporation Board Observer and Standstill Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]